

# Exodus-2, Mouse Recombinant

|                           |   |        |
|---------------------------|---|--------|
| <b>CATALOG #:</b>         | 7681-20   | 20 µg  |
|                           | 7681-100  | 100 µg |
|                           | 7681-1000   | 1 mg   |
| <b>ALTERNATE NAMES:</b>   | CCL21, 6Ckine   |        |
| <b>SOURCE:</b>            | E.Coli  |        |
| <b>PURITY:</b>            | ≥98% by SDS - PAGE  |        |
| <b>MOL. WEIGHT:</b>       | 12 kDa.   |        |
| <b>ENDOTOXIN CONTENT:</b> | Measured by kinetic LAL analysis and is typically ≤ 1 EU/µg protein |        |
| <b>FORM:</b>              | Lyophilized   |        |
| <b>FORMULATION:</b>       | Recombinant mouse Exodus-2 is lyophilized with no additives.        |        |

**RECONSTITUTION:** Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile water at a concentration of 0.1 mg/mL, which can be further diluted into other aqueous solutions.

**STORAGE CONDITIONS:** Lyophilized product is very stable at -20°C. Reconstituted material should be aliquoted and frozen at -20°C. It is recommended that a carrier protein (0.1% HSA or BSA) is added for long term storage.

**DESCRIPTION:** Exodus-2, also known as CCL21 and 6Ckine, is a novel chemokine produced at high levels in human lymph node tissue and the spleen. 6Ckine signals through the CCR7 receptor to recruit thymocytes and activated T cells in vitro, but is not known to be chemotactic for monocytes. Human and mouse Exodus-2 share > 85% amino acid homology. Recombinant mouse Exodus-2 is a nonglycosylated protein, containing 110 amino acids, with a molecular weight of 12 kDa.

**BIOLOGICAL ACTIVITY:** The activity is determined by its ability to chemoattract 5-10 day old cultures of human peripheral blood lymphocytes at concentrations between 200 ng/mL- 600 ng/mL.

**AMINO ACID SEQUENCE:** SDGGGQDCCL KYSQKKIPYS IVRGYRKQEP SLGCPAIL  
 FSPRKHSKPE LKANPEEGWV QNLMRRLDQP PAPGKQSPGC RKNRGTSKSG  
 KKGKGSKGCK RTFOTOPSRG




Figure: 1 µg of Mouse Exodus-2 was run under (+) reducing conditions and (-) non-reducing conditions in a 4-20% Tris-Glycine gel, stained with Coomassie Blue. Mouse Exodus-2 has a predicted MW of 12 kDa.

**RELATED PRODUCTS:**

- Exodus-2, human recombinant (Cat. No. 4031-20, 1000)
- Recombinant Human CCL23 (Cat. No. 4276-10, 50, 100)
- Recombinant Human CXCL10 (Cat. No. 4277-10, 50, 100)
- Recombinant Human CXCL14 (Cat. No. 4278-10, 50, 100)
- Eotaxin/CCL11, human recombinant (Cat. No. 4028-20, 100, 1000)
- Eotaxin/CCL11, murine recombinant (Cat. No. 4029-10, 1000)
- RANTES, human recombinant (Cat. No. 4321-10, 1000)
- RANTES, murine recombinant (Cat. No. 4322-10, 1000)
- RANTES, rat recombinant (Cat. No. 4323-20, 100, 1000)
- SDF-1alpha (CXCL12), human recombinant (Cat. No. 4387-10, 50, 1000)
- SDF-1alpha (CXCL12), murine recombinant (Cat. No. 4388-10, 50, 1000)
- SDF-1beta (CXCL12), human recombinant (Cat. No. 4390-10, 100, 1000)
- SDF-1beta (CXCL12), murine recombinant (Cat. No. 4391-10, 100, 1000)

**FOR RESEARCH USE ONLY! Not to be used in humans.**

